Professional Documents
Culture Documents
com
Original article
Matrix metalloproteinase-8 is the major potential collagenase
in active peri-implantitis
Hikaru Arakawa DDS, PhD, Junji Uehara DDS, PhD, Emilio Satoshi Hara DDS,
Wataru Sonoyama DDS, PhD, Aya Kimura DDS, PhD, Manabu Kanyama DDS, PhD,
Yoshizo Matsuka DDS, PhD, Takuo Kuboki DDS, PhD*
Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan
Received 21 January 2012; received in revised form 13 July 2012; accepted 30 July 2012
Abstract
Purpose: Current clinical procedures to control or regenerate bone loss due to peri-implantitis are not predictable neither accomplish complete
resolution. Therefore, early detection of the onset and the active periods of bone loss are crucial for prevention of extensive peri-implant bone
resorption. This study aimed to determine a possible association between the presence of collagenases (MMP-1, MMP-8 and MMP-13) in peri-
implant sulcular fluid (PISF) and active periods of bone loss by annually adjusted vertical bone loss (AVBL) measurements.
Methods: Intended sample consisted of 76 consecutive patients who received oral implant treatment at the Fixed Prosthodontic Clinic of Okayama
University Hospital from 1990 to 2000. Twelve subjects were lost to follow-up or refused to participate. Consequently, the actual sample consisted
of 64 patients who were followed-up for at least one year. Those patients with AVBL > 0.6 mm were included in the severe peri-implantitis group,
and randomly selected, age-, gender- and implantation site-matched healthy patients (AVBL < 0.3 mm) comprised the control group. PISF
samples were collected from both groups and further analyzed by western blot for detection of collagenases.
Results: Four patients presented severe peri-implantitis. MMP-8 was the only collagenase detected in peri-implant sites with ongoing bone loss.
PISF samples from control group showed no positive reactions to any collagenase.
Conclusion: This study showed MMP-8 as a possible marker for progressive bone loss in peri-implantitis.
# 2012 Japan Prosthodontic Society. Published by Elsevier Ireland. Open access under CC BY-NC-ND license.
Keywords: Dental implant; Peri-implantitis; Peri-implant sulcular fluid; Matrix metalloproteinase (MMP)
1883-1958 # 2012 Japan Prosthodontic Society. Published by Elsevier Ireland. Open access under CC BY-NC-ND license.
http://dx.doi.org/10.1016/j.jpor.2012.07.002
250 H. Arakawa et al. / Journal of Prosthodontic Research 56 (2012) 249–255
Fig. 1. The preliminary validation study on PISF sampling method. (A) Examination protocol for the PISF sampling method. The preliminary study showed that the
most appropriate method (lane 1) was to carefully remove visible supra-gingival plaque and mildly dry the sampling site (mesio-buccal corner) by air spray in order to
remove saliva or blood from the sampling site. Paper strips were then gently inserted approximately 1 mm into the peri-implant sampling sites and kept in place for
30 s; GC, gingival crevice. (B) Collected samples were separated by SDS-PAGE, and detected by sliver staining. Sampling efficacy was higher in the conditions
utilizing a PBS-T solution (lanes 1, 2, 5 and 7) compared to PBS (lanes 3, 4 and 6). Numerous bands were observed in lanes 5 and 7 due to contamination of saliva and
blood in the PISF sampling process.
metalloproteinases (MMPs) [14–17]. MMP family comprises from 1990 to 2000. Exclusion criteria were subjects who
five subgroups (collagenases, gelatinases, stromelyins, matrily- received prosthesis (or functional loading) for less than one
sins and membrane-type MMPs) and is known by its capability to year prior to the study onset, unwilling to participate, with
degrade almost all extracellular matrix and basement membrane systemic diseases such as diabetes, immunodeficiency and
molecules both in physiologic tissue repair and pathologic tissue osteoporosis, and who had undergone irradiation therapy. In
destruction [18–24]. response, 12 patients were excluded and the remaining 64
The collagenase subgroup is composed mainly by MMP-1, subjects constituted the actual study sample. All subjects
MMP-8 and MMP-13, and is of particularly relevance in both were explained about the objectives of this study and signed
periodontitis and peri-implantitis conditions due to their the informed consent. The Ethics Committee of Okayama
capability to cleave native fibrillar collagens (types I, II, III, University Graduate School of Medicine, Dentistry and
and V) as well as various non-collagenous molecules Pharmaceutical Sciences approved the research protocol
[20,22,23]. Previous studies have reported an upregulation (#729).
of these collagenases in gingivitis, early-onset (juvenile) All patients were followed-up for at least one year at a
periodontitis, adult periodontitis and peri-implantitis [25–36]. frequency of 6–12 months. In order to assess periodically bone
However, most studies on peri-implantitis were cross- levels, radiographic images were taken from all patients by
sectional, lacked control group with healthy-implant patients, well-trained technicians using the parallel method at every
or did not measure progressive/ongoing peri-implant bone follow-up return. Bone level measurements (radiographic
loss. Therefore, the purpose of this longitudinal study was to image analyses) were calculated by three pre-calibrated
analyze if MMP-1, MMP-8 and MMP-13 are detectable in experienced dentists in a blind manner, and determined by
peri-implant sulcular fluids (PISFs) of healthy and diseased the distances between the alveolar bone crest and the respective
sites, as well as to investigate the association between the tooth cusp. Measurements were performed for the distal and
possible presence of these aforementioned MMPs and ongoing mesial sites, and were represented by the average of these two
bone loss measured by annually adjusted vertical bone loss values.
(AVBL) measurements. The annually adjusted vertical bone loss (AVBL) was
measured by subtraction of two consecutive bone level
2. Materials and methods measurements, i.e., current minus immediately previous bone
level. Positive AVBL values indicated progressive peri-implant
2.1. Patients and AVBL bone loss, whereas negative AVBL values corresponded to
progressive peri-implant bone regeneration. Each implant was
Intended sample consisted of 76 consecutive patients who classified into three groups according to the AVBL measure-
received implant treatment (IMZ implants, Friatec1, ments: severe peri-implantitis group (AVBL > 0.6 mm), mild
Friedrichsfeld, Germany; or Brånemark system implant, peri-implantitis group (0.3 mm < AVBL < 0.6 mm) and
Nobel Biocare1, Gothenburg, Sweden) at the Fixed healthy group (AVBL < 0.3 mm). For calculation of peri-
Prosthodontic Clinic of Okayama University Dental Hospital implantitis incidence, in case of multiple implantation sites, the
H. Arakawa et al. / Journal of Prosthodontic Research 56 (2012) 249–255 251
Table 1
Demographic information of the peri-implantitis and control patients.
Subject Age Sex Functioning Implant site Lane Baseline AVBL at the first AVBL at the second Total protein
(years) period (year) number AVBL MMP analysis MMP analysis (mg/mL)
Peri-implantitis patients
A 68 M 6.83 R-Man-1st 1 0.23 0.14 0.60 306
6.83 R-Man-2nd 2 0.66 1.98 0.51 425
B 65 F 4.83 L-Man-1st 3 1.16 0.81 0.01 438
4.83 L-Man-2nd 4 0.23 0.58 0.58 278
C 63 F 1.67 R-Max-1st 5 2.40 8.55 8.55 525
1.67 R-Max-2nd 6 0.84 0.50 0.50 312
D 78 M 7.42 R-Man-2nd 7 0.59 0.30 – 247
4.25 L-Man-1st 8 0.85 0.14 – 308
4.25 L-Man-2nd 9 0.68 0.35 – 375
Mean 68.50 4.73 0.84* 357.11*
S.D. 6.65 2.09 0.65 90.20
Control patients
E 66 M 1.00 L-Man-2nd 10 0 – – 227
1.00 L-Man-3rd 11 0 – – 240
F 59 F 4.42 L-Man-1st 12 0 – – 191
4.42 L-Man-2nd 13 0.07 – – 237
G 65 F 2.75 R-Man-1st 14 0.11 – – 187
2.75 R-Man-2nd 15 0 – – 224
H 74 M 2.42 R-Man-1st 16 0.25 – – 207
2.42 R-Man-2nd 17 0 – – 125
Mean 66.00 2.64 0.05* 204.75*
S.D. 6.16 1.30 0.09 37.83
AVBL, annually adjusted vertical bone loss; R, right; L, left; Max, maxillary; Man, mandibular; 1st, first molar; 2nd, second molar; 3rd, third molar; –, data not taken.
Severe peri-implantitis cases (AVBL > 0.6 mm) are highlighted in bold numbers.
*
p < 0.05 (t-test) relative to control group.
worst peri-implant site condition determined patient’s peri- 2.3. PISF sample collection and analysis
implantitis severity.
PISF sampling was performed at two different time-points
2.2. Preliminary validation of PISF sampling procedure by three distinct dentists. Initial PISF samples were collected
from all implant sites of peri-implantitis patients and compared
Prior to actual PISF sampling, a preliminary validation study to randomly-selected healthy controls matched by age, gender
was carried out to determine the best clinical sampling strategy and the implantation site. Peri-implantitis patients were then
(Fig. 1). PISF samples were collected from one patient according submitted to mechanical peri-implant scaling and anti-
to the clinical steps shown in Fig. 1A. The optimal sampling microbial treatment by a subgingival application of minocy-
efficacy (Fig. 1B) was obtained when utilizing a phosphate- cline hydrochloride (Periocline1, Sunstar, Osaka, Japan), and,
buffered saline containing Tween-20 (PBS-T) solution (lanes 1, subsequently, to second PISF sampling for re-assessment of
2, 5 and 7) compared to PBS solution. On the other hand, possible changes in the presence/absence of collagenases.
numerous bands were observed in lanes 5 and 7 probably due to Collagenase presence were analyzed by western blotting
saliva and blood contamination during the sampling process. with anti-human monoclonal antibodies specific for MMP-1,
Therefore, the most appropriate sampling method (lane 1) was to MMP-8 and MMP-13 with positive controls [37]. In brief,
carefully remove any visible supra-gingival plaque, mildly dry samples were initially electrophoresed in SDS gel (10%) under
the sampling site (mesio-buccal corner) by air-spray in order to reducing conditions. Proteins were transferred onto a poly-
remove saliva or blood from the peri-implant site, and vinilidene-difluoride membrane and blocked for 1 h with 10%
subsequently insert paper strips (Diadent1, Seoul, Korea) gently skim milk in PBS-T. The blocked membrane was incubated
into approximately 1 mm of the mesio-buccal corner of the peri- with anti-human MMP-1 (1 mg/mL), MMP-8 (10 mg/mL) and
implant sulcus, keeping it in place for 30 s. MMP-13 (2 mg/mL) monoclonal antibodies (Fuji Chemical
Collected samples were separated by sodium dodecyl Industry, Takaoka, Japan), diluted with 10% skim milk in PBS-
sulfate-polyacrylamide (SDS-PAGE) and detected by a silver T and incubated overnight. The membrane was washed 3 times
stain kit (BIO-RAD, Hercules, CA, USA), further dissolved in a with PBS-T, and incubated with peroxidase-conjugate anti-
300 mL solution of PBS-T and stored at 20 8C for further mouse IgG (1/2000 dilution in PBS-T, Amersham Life Science,
analysis. The total amount of protein was assessed using a BCA Little Chalfort, Buckinghamshire, England) for 1 h at 37 8C.
Protein Assay Reagent kit (PIERCE, Rockford, IL, USA). Finally, the membrane was washed 3 times with PBS-T,
252 H. Arakawa et al. / Journal of Prosthodontic Research 56 (2012) 249–255
Fig. 3. Initial PISF analysis for MMP-8. The 85 kDa band corresponding to
latent MMP-8 was observed in lanes 2, 3 and 5 of patients A, B and C,
respectively. However, the 64 kDa band corresponding to active MMP-8 was
observed only in lane 3 (patient B). No band equivalent to MMP-8 was observed
either in the lanes of patient D or in control group.
4. Results
developed by ECL plus reagent (Amersham Life Science, GE Fig. 2 shows radiographic images of the 4 peri-implantitis
Healthcare, USA) and exposed to ECL Hyperfilm1 (Kodak, subjects with notable vertical bone loss around the active peri-
Tokyo, Japan). implantitis sites (implants 2, 3, 5, 6, 8 and 9) compared to
inactive peri-implantitis sites (implants 1, 4 and 7). Charts
demonstrate the total accumulated amount of bone loss (TABL)
3. Statistics with notable periods of active bone resorption.
Baseline data comparison between peri-implantitis and 4.3. PISF sample analysis
healthy control groups was performed by t-tests for indepen-
dent samples, using SPSS version 17.0 (SPSS Japan Inc.). Fig. 3 shows western blotting results of the first PISF
Significant level was set as a = 0.05. sampling. The 85 kDa band corresponding to pro-MMP-8 was
H. Arakawa et al. / Journal of Prosthodontic Research 56 (2012) 249–255 253
Fig. 4. Initial PISF analysis for MMP-1 and MMP-13. MMP-1 and MMP-13 were not detected in any PISF sample.
the latter case, and consequently, MMP-8 was detected only in could possibly mask the exact bands corresponding to MMPs
this case. [39]. Therefore, research is ongoing to determine the solutions
After mechanical and anti-microbial peri-implant treatment, for optimal detection of several types of MMPs.
AVBL measurements and PISF samples were again collected Another point to consider in this study is that classification
from patients A, B and C. Calculation of AVBL measurements of peri-implantitis groups was based exclusively on radio-
demonstrated normalization of bone loss in patients A and B. graphic images, which are subjected to intrinsic distortions as
On the other hand, patient C, unfortunately, was unable to well as sensitivity of the techniques applied. Nevertheless,
attend the peri-implantitis treatment follow-up returns due to Esposito et al. [41] reported that well-performed and well-
hospitalization. Consequently, patient C continued presenting analyzed radiographic images are more reliable than other
with severe peri-implantitis in implant 5, which was lost 6 clinical parameters such as peri-implant probing depth or
months after the second PISF sampling, whereas implant 6 bleeding. For example, probing depth may be difficult to be
presented AVBL < 6 mm. performed around implant screws, especially in severe bone
This situation, however, unexpectedly enabled inter-indivi- loss cases in which the threads have already been reached [41].
dual comparison between this particular patient and the other Additionally, other clinical classifications such as bleeding and
two that received peri-implantitis treatment. Western blot gingival index have been reported not to directly correlate with
analysis of the second PISF samples again detected MMP-8 the severity of bone loss [31].
only in implant 5 of patient C (Fig. 3). MMP-8 could not be
detected either in the intra-individual implant control (implant 6. Conclusion
6) or in the implants of patients A and B (Table 1 and Fig. 3).
These results demonstrated that MMP-8 was the only This study showed that MMP-8 is the major collagenase
collagenase associated with severe peri-implantitis during present in PISF of active peri-implantitis sites. Future studies
ongoing periods of bone loss. This association, however, does with larger study samples are necessary to confirm this possible
not necessarily imply that MMP-8 directly degrades the peri- role of MMP-8 as a predictor for active periods of peri-
implant tissues in situ, because the western blot results showed implantitis alveolar bone loss. Additionally, analysis of the risk
MMP-8 mostly in its pro-active (latent) form. factors for MMP-8 unbalance, as well as a deeper insight into
As seen in Fig. 3, active MMP-8 was observed only in the molecular interactions among MMPs, other inflammatory
implant 3 of patient B, which coincided with a terminal phase of cytokines, microorganisms and peri-implant tissues should also
bone resorption (Fig. 2). On the other hand, latent MMP8 was be investigated.
detected in implants 2 and 5 of patients A and C, respectively,
and corresponded to active phase of bone resorption. A possible Conflict of interest
reasoning for active MMP8 being detected in terminal phase is
based on data of recent studies that demonstrated that MMP8 All authors have no conflict of interest.
could also act as a protector of bone resorption [40]. Kuula et al.
demonstrated that MMP8 knock-out mice presented more Acknowledgements
extensive alveolar bone resorption caused by bacterial infection
compared to wild type controls [40]. Therefore, MMP8 could This study was partially supported by a Grant-in-Aid
act as an inhibitor of bacterium-induced peri-implant tissue (#13672031, #15592049, #17592025) from the Japan Society
destruction, and therefore be in its active form in the terminal for the Promotion of Science.
phase of bone resorption.
MMP-1 and MMP-13 could not be detected in any PISF References
sample (Fig. 4). This is in corroboration with previous reports
using western blotting which also showed negative MMP-1 [1] Kuboki T, Okamoto S, Suzuki H, Kanyama M, Arakawa H, Sonoyama W,
detectability in peri-implant tissues [21]. On the other hand, et al. Quality of life assessment of bone-anchored fixed partial denture
patients with unilateral mandibular distal-extension edentulism. J Prosthet
immunohistochemistry of peri-implantitis and healthy peri-
Dent 1999;82:182–7.
implant granulation tissues showed significant difference with [2] Strassburger C, Heydecke G, Kerschbaum T. Influence of prosthetic and
respect to quantitative immunolabelling for MMP-13, but for implant therapy on satisfaction and quality of life: a systematic literature
MMP-1 [25]. Nevertheless, that study utilized granulation review. Part 1. Characteristics of the studies. Int J Prosthodont 2004;17:
tissues as subject’s samples, which definitely could attain great 83–93.
concentrations of MMPs; however, in terms of biomarker utility [3] Berglundh T, Persson L, Klinge B. A systematic review of the incidence of
biological and technical complications in implant dentistry reported in
in a clinical setting, the authors believe that PISF sampling is prospective longitudinal studies of at least 5 years. J Clin Periodontol
more convenient, simple and harmless compared to intra- 2002;29(Suppl. 3):197–212 [discussion 232–193].
granulation tissue sampling procedure. [4] Bragger U, Aeschlimann S, Burgin W, Hammerle CH, Lang NP. Biologi-
Other reasons for undetectability of MMP-1 and MMP-13 cal and technical complications and failures with fixed partial dentures
could be associated with the limited sample size as well as the (FPD) on implants and teeth after four to five years of function. Clin Oral
Implants Res 2001;12:26–34.
solutions utilized in this present investigation. A previous study [5] Ferreira SD, Silva GL, Cortelli JR, Costa JE, Costa FO. Prevalence and
reported that MMP detectability was very sensitive to methods risk variables for peri-implant disease in Brazilian subjects. J Clin Period-
and materials, especially medium and/or buffer solutions which ontol 2006;33:929–35.
H. Arakawa et al. / Journal of Prosthodontic Research 56 (2012) 249–255 255
[6] Roos-Jansaker AM, Lindahl C, Renvert H, Renvert S. Nine- to fourteen- [26] Ingman T, Tervahartiala T, Ding Y, Tschesche H, Haerian A, Kinane DF,
year follow-up of implant treatment. Part II. Presence of peri-implant et al. Matrix metalloproteinases and their inhibitors in gingival crevicular
lesions. J Clin Periodontol 2006;33:290–5. fluid and saliva of periodontitis patients. J Clin Periodontol 1996;23:
[7] Lindhe J, Berglundh T, Ericsson I, Liljenberg B, Marinello C. Experi- 1127–32.
mental breakdown of peri-implant and periodontal tissues. A study in the [27] Kiili M, Cox SW, Chen HY, Wahlgren J, Maisi P, Eley BM, et al.
beagle dog. Clin Oral Implants Res 1992;3:9–16. Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult peri-
[8] Berglundh T, Gislason O, Lekholm U, Sennerby L, Lindhe J. Histopatho- odontitis: molecular forms and levels in gingival crevicular fluid and
logical observations of human periimplantitis lesions. J Clin Periodontol immunolocalisation in gingival tissue. J Clin Periodontol 2002;29:
2004;31:341–7. 224–32.
[9] Deppe H, Horch HH, Neff A. Conventional versus CO2 laser-assisted [28] Kivela-Rajamaki M, Maisi P, Srinivas R, Tervahartiala T, Teronen O, Husa
treatment of peri-implant defects with the concomitant use of pure-phase V, et al. Levels and molecular forms of MMP-7 (matrilysin-1) and MMP-8
beta-tricalcium phosphate: a 5-year clinical report. Int J Oral Maxillofac (collagenase-2) in diseased human peri-implant sulcular fluid. J Periodon-
Implants 2007;22:79–86. tal Res 2003;38:583–90.
[10] Kotsovilis S, Karoussis IK, Trianti M, Fourmousis I. Therapy of peri- [29] Kivela-Rajamaki MJ, Teronen OP, Maisi P, HUsa V, Tervahartiala TI,
implantitis: a systematic review. J Clin Periodontol 2008;35:621–9. Pirila EM, et al. Laminin-5 gamma2-chain and collagenase-2 (MMP-8)
[11] Lindhe J, Meyle J. Peri-implant diseases: Consensus Report of the Sixth in human peri-implant sulcular fluid. Clin Oral Implants Res 2003;14:
European Workshop on Periodontology. J Clin Periodontol 2008;35(Suppl. 158–65.
8):282–5. [30] Leite MF, Santos MC, de Souza AP, Line SR. Osseointegrated implant
[12] Renvert S, Polyzois I, Maguire R. Re-osseointegration on previously failure associated with MMP-1 promotor polymorphisms ( 1607 and
contaminated surfaces: a systematic review. Clin Oral Implants Res 519). Int J Oral Maxillofac Implants 2008;23:653–8.
2009;20(Suppl. 4):216–27. [31] Ma J, Kitti U, Hanemaaijer R, Teronen OP, Sorsa TA, Natah S, et al.
[13] Sahrmann P, Attin T, Schmidlin PR. Regenerative treatment of peri- Gelatinase B is associated with peri-implant bone loss. Clin Oral Implants
implantitis using bone substitutes and membrane: a systematic review. Res 2003;14:709–13.
Clin Implant Dent Relat Res 2011;13:46–57. [32] Santos MC, Campos MI, Souza AP, Trevilatto PC, Line SR. Analysis of
[14] Klinge B, Gustafsson A, Berglundh T. A systematic review of the effect of MMP-1 and MMP-9 promoter polymorphisms in early osseointegrated
anti-infective therapy in the treatment of peri-implantitis. J Clin Period- implant failure. Int J Oral Maxillofac Implants 2004;19:38–43.
ontol 2002;29(Suppl. 3):213–25 [discussion 232–3]. [33] Silva N, Dutzan N, Hernandez M, Dezerega A, Rivera O, Aquillon JC,
[15] Norowski Jr PA, Bumgardner JD. Biomaterial and antibiotic strategies for et al. Characterization of progressive periodontal lesions in chronic
peri-implantitis: a review. J Biomed Mater Res B Appl Biomater 2009;88: periodontitis patients: levels of chemokines, cytokines, matrix metallo-
530–43. proteinase-13, periodontal pathogens and inflammatory cells. J Clin
[16] Pye AD, Lockhart DE, Dawson MP, Murray CA, Smith AJ. A review of Periodontol 2008;35:206–14.
dental implants and infection. J Hosp Infect 2009;72:104–10. [34] Sorsa T, Hernandez M, Leppilahti J, Munjal S, Netuschil L, Mantyla P.
[17] Quirynen M, De Soete M, van Steenberghe D. Infectious risks for oral Detection of gingival crevicular fluid MMP-8 levels with different labo-
implants: a review of the literature. Clin Oral Implants Res 2002;13:1–19. ratory and chair-side methods. Oral Dis 2010;16:39–45.
[18] Giannobile WV. Host-response therapeutics for periodontal diseases. J [35] Teronen O, Konttinen YT, Lindqvist C, Salo T, Ingman T, Lauhio A, et al.
Periodontol 2008;79(Suppl. 8):1592–600. Human neutrophil collagenase MMP-8 in peri-implant sulcus fluid and its
[19] Hannas AR, Pereira JC, Granjeiro JM, Tjaderhane L. The role of matrix inhibition by clodronate. J Dent Res 1997;76:1529–37.
metalloproteinases in the oral environment. Acta Odontol Scand 2007;65: [36] Xu L, Yu Z, Lee HM, Wolff MS, Golub LM, Sorsa T, et al. Characteristics
1–13. of collagenase-2 from gingival crevicular fluid and peri-implant sulcular
[20] Krane SM, Inada M. Matrix metalloproteinases and bone. Bone 2008;43: fluid in periodontitis and peri-implantitis patients: pilot study. Acta
7–18. Odontol Scand 2008;66:219–24.
[21] Nomura T, Ishii A, Shimizu H, Taguchi N, Yoshie H, Kusakari H, et al. [37] Kanyama M, Kuboki T, Kojima S, Fujisawa T, Hattori T, Takigawa M,
Tissue inhibitor of metalloproteinases-1, matrix metalloproteinases-1 and et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases
-8, and collagenase activity levels in peri-implant crevicular fluid after in synovial fluids of patients with temporomandibular joint osteoarthritis. J
implantation. Clin Oral Implants Res 2000;11:430–40. Orofac Pain 2000;14:20–30.
[22] Sorsa T, Mäntylä P, Rönkä H, Kallio P, Kallis GB, Lundqvist C, et al. [38] Jung RE, Pjetursson BE, Glauser R, Zembic A, Zwahlen M, Lang NP. A
Scientific basis of a matrix metalloproteinase-8 specific chair-side test for systematic review of the 5-year survival and complication rates of implant-
monitoring periodontal and peri-implant health and disease. Ann N Y supported single crowns. Clin Oral Implants Res 2008;19:119–30.
Acad Sci 1999;878:130–40. [39] Aboyoussef H, Carter C, Jandinski JJ, Panagakos FS. Detection of
[23] Sorsa T, Tjaderhane L, Konttinen YT, Lauhio A, Salo T, Lee HM, et al. prostaglandin E2 and matrix metalloproteinases in implant crevicular
Matrix metalloproteinases: contribution to pathogenesis, diagnosis and fluid. Int J Oral Maxillofac Implants 1998;13:689–96.
treatment of periodontal inflammation. Ann Med 2006;38:306–21. [40] Kuula H, Salo T, Pirila E, Tuomainen AM, Jauhiainen M, Uitto VJ, et al.
[24] Sorsa T, Tjaderhane L, Salo T. Matrix metalloproteinases (MMPs) in oral Local and systemic responses in matrix metalloproteinase 8-deficient mice
diseases. Oral Dis 2004;10:311–8. during Porphyromonas gingivalis-induced periodontitis. Infect Immun
[25] Borsani E, Salgarello S, Mensi M, Boninsegna R, Stacchiotti A, Rezzani 2009;77:850–9.
R, et al. Histochemical and immunohistochemical evaluation of gingival [41] Esposito M, Hirsch JM, Lekholm U, Thomsen P. Biological factors
collagen and metalloproteinases in peri-implantitis. Acta Histochem contributing to failures of osseointegrated oral implants. (II). Etiopatho-
2005;107:231–40. genesis. Eur J Oral Sci 1998;106:721–64.